Potent antimalarials with development potential identified by structure-guided computational optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series
Publication: Journal of Medicinal Chemistry
Solvent-Dependent Photophysics and Reactivity of Monomeric and Dimeric 4-Amino-1,8-Naphthalimides
Publication: The Journal of Physical Chemistry A
Synthetic platform for mono-functionalised tridentate macrocycles as key precursors of mechanically-linked macromolecular systems
Publication: Organic Chemistry Frontiers
US FDA approved drugs from 2015-June 2020-A perspective
Publication: Journal of Medicinal Chemistry
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia
Publication: Leukemia
A novel reactor configuration for continuous virus inactivation
Publication: Biochemical Engineering Journal
Palladium‐Catalyzed Reductive Carbonylation of (Hetero) Aryl Halides and Triflates Using Cobalt Carbonyl as CO Source
Publication: Europen Journal of Organic Chemistry
Lead Optimization of a Pyrrole-Based Dihydroorotate
Publication: Journal of Medicinal Chemistry
How Syngene helped develop the world’s first drug for a rare disease affecting children
Learn how Syngene partnered with a U.S.-based biotech company to develop and manufacture a first-in-class treatment for a rare disease affecting children.
Accelerating PROTAC programs to drug the “undruggable”
Syngene offers expertise in all aspects of PROTACs – from designing of small molecules to their synthesis, lead optimization, and ultimate candidate delivery at an accelerated pace.